All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
Lucerasta is the galactose form of Miglustat, an orally active inhibitor of glucosylceramide synthase (GCS).Lucerastat has potential for use in Fabry disease research.
| Molecular Weight | 219.28 |
| Formula | C10H21NO4 |
| CAS Number | 141206-42-0 |
| Storage | -20°C, dry, sealed |
[1] Frank Weidemann, et al. Int J Mol Sci. Chaperone Therapy in Fabry Disease
[2] Malte Lenders, et al. Drugs. Fabry Disease: The Current Treatment Landscape
[4] M Michaud, et al. Rev Med Interne. [Fabry disease: A review]
[5] Sanne J van der Veen, et al. J Inherit Metab Dis. Developments in the treatment of Fabry disease
| Related Glucosylceramide Synthase Products |
|---|
| Eliglustat
Eliglustat inhibits glucosylceramide synthase (GCS), thus reducing the load of glucosylceramide influx into the lysosome. |
| Ibiglustat
Ibiglustat (Venglustat) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. |
| G43
G43 is a potent, selective glucosyltransferase inhibitor, with the Kd of 3.7μM and 46.9 nM for GtfB and GtfC, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
